AI Article Synopsis
- - The BNT162b2 (Pfizer-BioNTech) vaccine showed over 90% efficacy in clinical trials for children and adolescents aged 5-17, but real-world effectiveness, especially against the Omicron variant, is still being evaluated.
- - In a study analyzing data from over 39,000 encounters, vaccine effectiveness (VE) for children aged 5-11 was 46% shortly after the second dose, while adolescents aged 12-15 had a VE of 83% and those aged 16-17 had a VE of 76% during similar timeframes.
- - VE significantly decreased after 150 days post-second dose during the Omicron variant's dominance, but improved to
Article Abstract
The efficacy of the BNT162b2 (Pfizer-BioNTech) vaccine against laboratory-confirmed COVID-19 exceeded 90% in clinical trials that included children and adolescents aged 5-11, 12-15, and 16-17 years (1-3). Limited real-world data on 2-dose mRNA vaccine effectiveness (VE) in persons aged 12-17 years (referred to as adolescents in this report) have also indicated high levels of protection against SARS-CoV-2 (the virus that causes COVID-19) infection and COVID-19-associated hospitalization (4-6); however, data on VE against the SARS-CoV-2 B.1.1.529 (Omicron) variant and duration of protection are limited. Pfizer-BioNTech VE data are not available for children aged 5-11 years. In partnership with CDC, the VISION Network* examined 39,217 emergency department (ED) and urgent care (UC) encounters and 1,699 hospitalizations among persons aged 5-17 years with COVID-19-like illness across 10 states during April 9, 2021-January 29, 2022, to estimate VE using a case-control test-negative design. Among children aged 5-11 years, VE against laboratory-confirmed COVID-19-associated ED and UC encounters 14-67 days after dose 2 (the longest interval after dose 2 in this age group) was 46%. Among adolescents aged 12-15 and 16-17 years, VE 14-149 days after dose 2 was 83% and 76%, respectively; VE ≥150 days after dose 2 was 38% and 46%, respectively. Among adolescents aged 16-17 years, VE increased to 86% ≥7 days after dose 3 (booster dose). VE against COVID-19-associated ED and UC encounters was substantially lower during the Omicron predominant period than the B.1.617.2 (Delta) predominant period among adolescents aged 12-17 years, with no significant protection ≥150 days after dose 2 during Omicron predominance. However, in adolescents aged 16-17 years, VE during the Omicron predominant period increased to 81% ≥7 days after a third booster dose. During the full study period, including pre-Delta, Delta, and Omicron predominant periods, VE against laboratory-confirmed COVID-19-associated hospitalization among children aged 5-11 years was 74% 14-67 days after dose 2, with wide CIs that included zero. Among adolescents aged 12-15 and 16-17 years, VE 14-149 days after dose 2 was 92% and 94%, respectively; VE ≥150 days after dose 2 was 73% and 88%, respectively. All eligible children and adolescents should remain up to date with recommended COVID-19 vaccinations, including a booster dose for those aged 12-17 years.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8893336 | PMC |
| http://dx.doi.org/10.15585/mmwr.mm7109e3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
SIV Env RhmAbs + N-803 at ART initiation prolongs viral decay without disrupting reservoir establishment in SIV-infected infant macaques.
PLoS Pathog
January 2025
Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, United States of America.
The latent viral reservoir remains the major barrier to HIV cure, placing the burden of strict adherence to antiretroviral therapy (ART) on people living with HIV to prevent recrudescence of viremia. For infants with perinatally acquired HIV, adherence is anticipated to be a lifelong need. In this study, we tested the hypothesis that administration of ART and viral Envelope-specific rhesus-derived IgG1 monoclonal antibodies (RhmAbs) with or without the IL-15 superagonist N-803 early in infection would limit viral reservoir establishment in SIV-infected infant rhesus macaques.
View Article and Find Full Text PDFDisruptive effects of genistein and daidzein on steroidogenesis, testicular development and maturation of Cyprinus carpio (Linn, 1758) males.
Fish Physiol Biochem
January 2025
Fish Nutrition, Biochemistry and Physiology Division, ICAR-Central Institute of Fisheries Education, Versova, Andheri West, Mumbai, 400061, Maharashtra, India.
A 60-day feeding trial was conducted to evaluate the combined effect of dietary soy phytoestrogens, specifically genistein and daidzein, on the gonadal recrudescence and maturation of male Cyprinus carpio (Linnaeus, 1758). Adult male C. carpio (60 ± 10 g) were fed with a diet with no added genistein or daidzein (C), 110 mg/100 mg genistein (GL), 210 mg/100 g genistein (GH), 4 mg/100 g daidzein (DL), 8 mg/100 g daidzein (DH), combination of 110 mg/100 mg genistein and 4 mg/100 g daidzein (DGL, equivalent to 17.
View Article and Find Full Text PDFHumic acid from vermicompost effectively regulates the redox status and mitigates the progression of experimental periodontitis.
Naunyn Schmiedebergs Arch Pharmacol
January 2025
Postgraduate Program in Health Sciences (PPGCS), Federal University of the Jequitinhonha and Mucuri Valleys (UFVJM), Diamantina, Brazil.
The progression of periodontal disease (PD) involves the action of oxidative stress mediators. Antioxidant agents may potentially attenuate the development of this condition. Thus, we aimed to evaluate the effects of different doses of humic acid (HA), extracted from biomass vermicomposting, on redox status and parameters related to PD progression in rats.
View Article and Find Full Text PDFA Recombinant Antibody Against ALK2 Promotes Tissue Iron Redistribution and Contributes to Anemia Resolution in a Mouse Model of Anemia of Inflammation.
Am J Hematol
January 2025
Keros Therapeutics, Lexington, Massachusetts, USA.
Patients with chronic inflammation are burdened with anemia of inflammation (AI), where inflammatory cytokines inhibit erythropoiesis, impede erythropoietin production, and limit iron availability by inducing the iron regulator hepcidin. High hepcidin hinders iron absorption and recycling, thereby worsening the impaired erythropoiesis by restricting iron availability. AI management is important as anemia impacts quality of life and potentially affects morbidity and mortality.
View Article and Find Full Text PDFThe Potential Systemic Anti-Inflammatory Effect of Turmeric Dried Extract.
Endocr Metab Immune Disord Drug Targets
January 2025
DDR Research Clinic, Caserta, Italy.
Background: Curcumin is a polyphenolic compound derived from the food spice turmeric that has received interest from the medical and scientific world for its role in the management of several conditions. Clinical studies, in humans, have shown that ingested Curcumin is safe even at high doses (12 g/day), but it has poor bioavailability primarily due to poor absorption and rapid metabolism and elimination. Several strategies have been implemented to improve the bioavailability of Curcumin, for example, the combination of piperine in a complex with Curcumin, or the usage of formulations with phospholipid or liposomal complexes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!